SAN DIEGO, California – January 19, 2023. Stemedica a best-in-class manufacturer of ischemic tolerant, allogeneic mesenchymal stem cells (itMSC), announced today that it has initiated its “PHASE IIB/III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND,…
SAN DIEGO, Aug. 5, 2021 /PRNewswire/ — Stemedica a San Diego-based biotech company…
SAN DIEGO, Calif. — September 28, 2020 — Stemedica Cell has received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) approval for “A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess…
TOLEDO, Ohio, July 28, 2020 – ProMedica today announced the promising results of its new study that evaluated the use of stem cells in the treatment of adult COVID-19 patients. Eight patients elected to participate in a study under Emergency Investigational New Drug…
SANTA MONICA – April 20, 2020 – A single patient, emergency Investigational New Drug (IND) use was cleared by the U.S. Food and Drug Administration for the treatment of severe lung injury due to COVID-19 at the Providence Saint John’s Health Center, Santa Monica,…
San Francisco, CA – CONGRESS OF NEUROLOGICAL SURGEONS October 19, 2019 – October 23, 2019 – Study sponsor Stemedica a global biotechnology company that uses cGMP manufactured, ischemia-tolerant (itMSCs), bone marrow derived, allogeneic…
Study Sponsored by Stemedica SAN DIEGO, Calif. – (September 30, 2019) – Results from a study sponsored by Stemedica a global biotechnology…
Abstract Background and Purpose Stroke is a leading cause of long-term disability. Limited treatment options exist for patients with chronic stroke and substantial functional deficits. The current study examined safety and preliminary efficacy estimates of intravenous…
Stemedica Cell Technologies Reports Positive Data in Phase I/IIa Study of Allogeneic Stem Cells for Ischemic Stroke – itMSCs were safe and well tolerated in the study – – Results of the study are supportive of advancing clinical
program –…
Washington, D.C., April 18, 2018 – Clinical trial planning is underway at MedStar Heart & Vascular Institute to determine whether a novel stem cell therapy will improve heart function for patients with heart failure. MedStar Heart, in partnership with CardioCell,…
Initial Sites Are Emory University and University of California, Irvine SAN DIEGO, California, and Lausanne, Switzerland — July 27, 2016 — Stemedica and its subsidiary, Stemedica International S.A., a leader in the development of innovative…
Clinical trial to study the effects of Stemedica’s proprietary mesenchymal stem cells in patients with traumatic brain injury SAN DIEGO, California – May 18, 2016. Stemedica received an FDA investigational new drug (IND)…
